Trials / Completed
CompletedNCT02285504
Evaluate SAGE-547 in Female Participants With Severe Postpartum Depression
An Open-Label Proof-of-Concept Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of SAGE-547 Injection in the Treatment of Adult Female Patients With Severe Postpartum Depression
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 4 (actual)
- Sponsor
- Supernus Pharmaceuticals, Inc. · Industry
- Sex
- Female
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label proof-of-concept study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of SAGE-547 Injection in adult female participants diagnosed with severe postpartum depression (PPD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SAGE-547 | Intravenous injection |
Timeline
- Start date
- 2015-01-07
- Primary completion
- 2015-06-05
- Completion
- 2015-06-05
- First posted
- 2014-11-07
- Last updated
- 2025-09-15
- Results posted
- 2021-12-02
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02285504. Inclusion in this directory is not an endorsement.